Theratechnologies ( (THTX) ) has released its Q4 earnings. Here is a breakdown of the information Theratechnologies presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theratechnologies Inc., a specialty biopharmaceutical company, focuses on the commercialization of innovative therapies, primarily within the HIV treatment sector, with a strong emphasis on redefining standards of care.
In its latest earnings report for the fourth quarter and full fiscal year 2024, Theratechnologies announced a record positive Adjusted EBITDA of $20 million, surpassing its guidance. The company also achieved record quarterly revenue of $25 million and annual revenue of $85.9 million, reflecting its robust financial performance.
Key highlights from the report include a 12% year-over-year increase in EGRIFTA SV® sales, reaching $60.1 million, and a strategic move to in-license two new Ionis assets in Canada to bolster long-term growth. The company also secured $75 million in new credit facilities, enhancing its financial flexibility. Despite a net loss of $8.3 million, the company demonstrated significant improvements in its financial metrics compared to the previous year.
Looking ahead, Theratechnologies is optimistic about its growth prospects, driven by its foundational HIV business and new product additions. The management remains confident in its ability to navigate challenges, including potential supply disruptions and regulatory approvals, to sustain its upward trajectory.